1.15

0.86% -0.01

After Hours: 1.15

Fate Therapeutics Inc (FATE)

Overview News Price History Option Chain Financials Discussions Forecast

Fate Therapeutics Inc stock is traded at $1.15, with a volume of 1.02M. It is down -0.86% in the last 24 hours and down -25.81% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Previous Close:

$1.16

Open:

$1.17

24h Volume:

1.02M

Relative Volume:

0.51

Market Cap:

$191.44M

Revenue:

$13.45M

Net Income/Loss:

$-178.23M

P/E Ratio:

-0.697

EPS:

-1.65

Net Cash Flow:

$-132.53M

1W Performance:

+2.68%

1M Performance:

-25.81%

6M Performance:

-21.50%

1Y Performance:

-66.18%

1-Day Range:

$1.12

$1.17

1-Week Range:

$1.05

$1.1793

52-Week Range:

$0.6611

$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name

Fate Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (655)

Phone

858.875.1803

Address

12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA

Employee

181

Twitter

@fatethx

Next Earnings Date

2025-05-02

Latest SEC Filings

FATE's Discussions on Twitter

Compare FATE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FATE Fate Therapeutics Inc	1.15	191.44M	13.45M	-178.23M	-132.53M	-1.65
VRTX Vertex Pharmaceuticals Inc	468.85	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	567.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	314.94	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.24	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	250.30	28.51B	3.81B	-644.79M	-669.77M	-6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral
Jan-06-23	Downgrade	Stifel	Buy → Hold
Jan-06-23	Downgrade	Truist	Buy → Hold
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-10-22	Initiated	Canaccord Genuity	Buy
Aug-18-22	Resumed	Wells Fargo	Overweight
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-11-22	Resumed	BMO Capital Markets	Market Perform
Dec-15-21	Upgrade	Wedbush	Neutral → Outperform
Dec-07-21	Initiated	Cowen	Outperform
Nov-09-21	Upgrade	Citigroup	Neutral → Buy
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight
Jun-07-21	Upgrade	H.C. Wainwright	Neutral → Buy
May-07-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Jefferies	Buy
Feb-26-21	Initiated	BofA Securities	Buy
Feb-26-21	Downgrade	Wedbush	Outperform → Neutral
Feb-11-21	Downgrade	Citigroup	Buy → Neutral
Jan-27-21	Resumed	H.C. Wainwright	Neutral
May-13-20	Initiated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-09-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-30-19	Reiterated	Mizuho	Buy
Dec-09-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-12-19	Initiated	SunTrust	Buy
Nov-06-19	Downgrade	Wells Fargo	Outperform → Market Perform
Oct-01-19	Initiated	Stifel	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	Cantor Fitzgerald	Overweight
Jul-12-19	Initiated	Oppenheimer	Outperform
Jun-13-19	Initiated	Mizuho	Buy
Jun-07-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Buy
May-24-19	Resumed	Citigroup	Buy
Mar-28-19	Initiated	SVB Leerink	Outperform
Jan-03-19	Downgrade	Stephens	Overweight → Equal-Weight
Nov-05-18	Initiated	Jefferies	Buy
Aug-01-18	Initiated	Citigroup	Buy
Mar-06-18	Downgrade	H.C. Wainwright	Buy → Neutral

View All

Fate Therapeutics Inc Stock (FATE) Latest News

Jul 11, 2025

10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey

Jul 11, 2025

Jul 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025

Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest

Jul 03, 2025

Jun 30, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener

Jun 30, 2025

Jun 15, 2025

Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st

Jun 15, 2025

Jun 14, 2025

Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com

Jun 14, 2025

TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World

Jun 14, 2025

Jun 13, 2025

Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World

Jun 13, 2025

Jun 12, 2025

FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus

Jun 12, 2025

Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada

Jun 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025

Jun 11, 2025

Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada

Jun 11, 2025

Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus

Jun 11, 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times

Jun 11, 2025

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq

Jun 11, 2025

Fate’s FT819 shows promising results in lupus patients - Investing.com

Jun 11, 2025

Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan

Jun 11, 2025

Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025

Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025

Fate’s FT819 shows promising results in lupus patients By Investing.com - Investing.com UK

Jun 11, 2025

Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World

Jun 11, 2025

Jun 10, 2025

Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance

Jun 10, 2025

Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 10, 2025

Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 10, 2025

Jun 08, 2025

Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 08, 2025

Jun 06, 2025

Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 06, 2025

Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 06, 2025

Jun 05, 2025

Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel

Jun 05, 2025

Jun 04, 2025

ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 04, 2025

Jun 03, 2025

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN

Jun 03, 2025

May 31, 2025

Fate Therapeutics appoints new board member By Investing.com - Investing.com South Africa

May 31, 2025

May 30, 2025

Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down - Nasdaq

May 30, 2025

Fate Therapeutics appoints new board member - Investing.com

May 30, 2025

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewswire

May 30, 2025

May 29, 2025

Fate Therapeutics to present lupus treatment data at EULAR 2025 By Investing.com - Investing.com South Africa

May 29, 2025

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - The Manila Times

May 29, 2025

May 28, 2025